Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports

Just now November 17, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

This article discusses Tirzepatide (Zepbound), a new obesity treatment medication that has shown clinical success in moving over half of treated teenagers below the obesity threshold. The article is not related to Iran and contains no information about Iranian affairs, politics, economy, military, human rights, or international relations.

Tirzepatide (Zepbound) is a once-weekly injectable medication that hits two targets at once. This dual-action drug mimics the effects of two natural gut hormones in the body—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Working together, these hormones keep blood sugar in check, slow the movement of food through the gut and signal the brain about fullness, which helps manage appetite and food intake.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →